Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer (original) (raw)
Related papers
Diagnostic Value of Platelet–To-Lymphocyte Ratio in Prostate Cancer
Open Access Macedonian Journal of Medical Sciences
BACKGROUND: Previous studies demonstrated the promising value of platelet-to-lymphocyte (PLR) in prostate cancer. AIM: This study was conducted to evaluate its pre-biopsy values in predicting prostate cancer. METHODS: We included all benign prostatic hyperplasia (BPH) and prostate cancer (PCa) patients who underwent a prostate biopsy in Adam Malik Hospital between August 11th 2011 and August 31st 2015. The relationship between pre-biopsy variables which could be affecting the percentage of prostate cancer risk was evaluated, including age, prostate-specific antigen (PSA) level, and prostate volume (EPV). The PLR was calculated from the ratio of related platelets with their absolute lymphocyte counts. The values then analysed to evaluate their associations with the diagnosis of BPH and PCa. RESULTS: As many as 298 patients consisted of 126 (42.3%) BPH and 172 PCa (57.7%) patients are included in this study. Mean age for both groups are 66.36 ± 7.53 and 67.99 ± 7.48 years old (p = 0.6...
Open Journal of Urology, 2019
Background: In the diagnosis of prostatic diseases, the need for markers other than prostate specific antigen (PSA) has been increasing in recent years. So, we aimed to determine the predictive value, the neutrophil lymphocyte ratio, platelet-to-lymphocyte ratio and mean platelet volume before prostate biopsy in predicting the results of pathology. Transrectal ultrasound-guided biopsy of the prostate was performed because of high PSA values and compared values of these parameters to predict of pathology results. Methods: 2715 patients who underwent 10-12 quadrant transrectal ultrasound-guided prostate biopsies between January 2008 and January 2018 have been evaluated retrospectively. Patients were divided into groups according to the biopsy pathology results by benign (group 1), atypical small acinar proliferation (ASAP) (group 2) and prostate cancer (group 3). A total of 204 patients who were benign prostate hyperplasia in 71 patients (34.8%), atypical small acinar proliferation in 80 (39.21%) and prostate adenocarcinoma (PCa) in 53 patients (25.98%) were included in the study by systematic sampling. Before the biopsy total PSA (tPSA), free PSA (fPSA), rate of percentage of free to total prostate specific antigen (f/tPSA) rate, PSA density (PSA-D), white blood cell (WBC) count, blood neutrophil count (NC), blood lymphocyte count (LC), neutrophil lymphocyte ratio (NLR), mean platelet volume (MPV), platelet count (PLT) and platelet-to-lymphocyte ratio (PLR) were measured and compared in all groups. Differences in continuous variables were assessed using the ANOVA. Logistic regression was used to analyze the linear relationship between predictive variables and pathology results. P < 0.05 was considered statistically significant. Results: NLR and PLR values were lower in group 1 than group 2 and were found statistically significant between in group 1 and group 2 (p: 0.03 and p: 0.02, respectively). MPV value was found 1.7 times higher in patients who were diagnosed with ASAP pathology than
Are neutrophil-lymphocyte and platelet-lymphocyte ratios valuable in predicting prostate cancer?
Archives of Clinical and Experimental Surgery (ACES), 2016
Introduction Many clinical and laboratory parameters have been investigated to determine their utility in predicting prostate cancer. Today, prostate-specific antigen (PSA) and nomograms that employ PSA are both widely accepted; the PSA level has a high predictive value for prostate cancer. Another parameter, the PSA density, has also demonstrated a direct relationship with prostate cancer; a PSA density over 0.15 in patients with a PSA from 4-10 ng/cc and a suspicion of cancer upon digital rectal examination (DRE) following transrectal ultrasonography (TRUS) have been suggested as an indicator for prostate biopsy [1-3]. A study in patients with prostate cancer who had a PSA increase of 0.75 ng/cc or more in a year revealed a specific marker for prostate cancer, but this was not identified in those with a PSA that was lower than 4 ng/cc in patients who did not have a PSA velocity of at least 0.75 ng/cc [4]. Catalona and colleagues investigated patients with a PSA from 4-10 ng/cc along with a free/total PSA ratio that was below 25% independently of other clinical markers to determine the presence of cancer, and they
International Journal Of Medical Science And Clinical Invention, 2018
Introduction: Prostate cancer is one of the medical problems in male population, and is the second most common cancer. According to statistics, the prevalence of prostate cancer in Europe is 214 / 100,000 and the number of cases diagnosed each year is 2.6 million. High incidence of prostate cancer in Indonesia, made it necessary to find an examination that can be used widely in major health centers with good sensitivity and specificity. Platelet and lymphocyte counts are routinely performed in most clinical laboratories around the world, therefore we evaluate whether pretreatment PLR and NLR can predict prognosis for prostate cancer patients. Methods: This study was conducted by using cross sectional analytical method in Urology Department of Urology Division of H. Adam Malik General Hospital Medan from 2012 until 2017. We analyzed 70 samples that met inclusion and exclusion criteria with Spearman correlation test in SPSS Statistic 23. Results: From 70 samples that has been analyzed...
Canadian Urological Association Journal, 2015
Introduction: We evaluate the role of NLR prior to prostate biopsy to predict biopsy histology and Gleason score in patients with prostate cancer.Methods: In this retrospective study, we evaluated data of patients underwent prostate biopsy between May 2005 and March 2015. We collected the following data: age, prostate-specific antigen (PSA), biopsy histology, Gleason score (GS) in prostate cancer patients, neutrophil counts, and lymphocyte counts. Patients were grouped as benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis. The Chi square test was used to compare categorical variables and analysis of variance (ANOVA) was applied for continuous variables.Results: Data of 1836 patients were investigated. The mean age, total PSA and neutrophil-lymphocyte ratio (NLR) of the population were 66.8 ± 8.17 years, 9.38 ± 4.7 ng/dL, and 3.11 ± 1.71, respectively. Patients were divided as follows: 625 in the group with BPH history, 600 in the prostatitis group, and 611 in the p...
Open Access Macedonian Journal of Medical Sciences
BACKGROUND: Over the past decades, the study of the microenvironment of cancer has supported the hypothesis between inflammation and cancer. Previous studies have demonstrated a promising value of platelet-to-lymphocyte (PLR) and neutrophil-to-lymphocyte ratio (NLR) as a systemic inflammatory response in prostate cancer. AIM: To evaluate their pre-biopsy values of PLR and NLR in predicting prostate cancer. MATERIAL AND METHODS: This is a diagnostic study with retrospective design. We included all benign prostatic hyperplasia (BPH) and prostate cancer (PCa) patients who underwent prostate biopsy in Adam Malik Hospital between August 2011 and August 2015. We used PSA value above 4 ng/dL as the threshold for the biopsy candidates. The relationship between pre-biopsy variables affecting the percentage of prostate cancer risk was evaluated, including age, prostate-specific antigen (PSA) level, and estimated prostate volume (EPV). The PLR and NLR were calculated from the ratio of related ...
Erciyes Medical Journal, 2018
Objective: Inflammation plays a critical role in the development and progression of cancer. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are easily accessible basic inflammatory parameters. In this study, we aimed to analyze the association between the NLR, PLR, and the Gleason score in prostate cancer, which is main parameter used in the prostate cancer prognosis. Materials and Methods: A total of 173 patients with prostate cancer (mean age, 63±6.2 years) who underwent radical prostatectomy were included into this retrospective study. The NLR and PLR were derived from the complete blood cell count results from the preoperative period. Patients were divided into two groups, as the low grade prostate cancer (Gleason score≤7 [3+4]) and the high-grade prostate cancer (Gleason score≥7 [4+3]) group. A logistic regression analysis was performed to determine the association. Results: A univariate logistic regression analysis showed that the Ln-prostate specific antigen (PSA) (1.83, 95% confidence interval [CI] [1.01, 3.3] p=0.04), Ln-lymphocyte (0.38, 95% CI [0.15, 0.94] p=0.03), and Ln-NLR (1.9, 95% CI 1.9 [1.13, 3.38] p=0.01) levels were significantly associated with the high-grade Gleason score. However, the Ln-PLR levels revealed the association with marginal statistical significance (2.06, 95 % CI [0.95, 4.4] p=0.06). In multiple analyses, after adjusting the analysis for age, Ln-NLR (1.96, 95% CI [1.12, 3.42] p=0.01) and Ln-lymphocyte levels (0.38, 95% CI [0.15, 0.97] p=0.04) were still statistically significantly associated with high-grade prostate cancer. Conclusion: Higher NLR levels were significantly associated with high-grade prostate cancer. However, PLR levels were not a significant predictor of higher Gleason scores.
Current Oncology
Purpose: To prospectively evaluate the albumin/globulin ratio (AGR), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) diagnostic and prognostic predictive value in a stratified population of prostate cancer (PC) cases. Methods: Population was divided based on the clinical and histologic diagnosis in: Group A: benign prostatic hyperplasia (BPH) cases (494 cases); Group B: all PC cases (525 cases); Group B1: clinically significant PC (426 cases); Group B2: non-metastatic PC (416 cases); Group B3: metastatic PC (109 cases). NLR, PLR, and AGR were obtained at the time of the diagnosis, and only in cases with PC considered for radical prostatectomy, determinations were also repeated 90 days after surgery. For each ratio, cut-off values were determined by receiver operating characteristics curve (ROC) analysis and fixed at 2.5, 120.0, and 1.4, respectively, for NLR, PLR, and AGR. Results: Accuracy in predictive value for an initial diagnosis of clinically significant...
The Bulletin of Urooncology, 2019
The aim of this study was to assess the usefulness of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), plateletto-lymphocyte ratio (PLR) and neutrophil-to-monocyte (NMR) as biomarkers in men who had a prostate-specific antigen (PSA) level of 4 to 10 ng/mL and who subsequently underwent prostate biopsy. Materials and Methods: We retrospectively analyzed the records of 546 patients who underwent multicore (≥12) TRUS-guided biopsy at our institution between April 2010 and November 2017. Age, PSA level, f/t PSA, NLR, PLR, LMR, NMR, Gleason score in patients with prostate cancer (PCa) and biopsy results were collected. Histological results were categorized into three groups as benign prostatic hyperplasia, prostatitis and PCa. Results: The median age of patients was 64 years. The mean total PSA level and f/t PSA ratio were 6.52±1.76 and 0.2±0.09, respectively. The mean NLR, LMR, PLR and NMR were 2.46±1.46, 3.94±2.07, 120.69±60.73 and 8.52±7.97, respectively. The f/t PSA ratio in the PCa group was significantly lower compared to the other two groups (p<0.001). There was no statistically difference in NLR, LMR, PLR and NMR values (p=0.293, p=0.066, p=0.189 and p=0.334, respectively). Multivariate logistic regression analysis showed that age, PLR and f/t PSA were more likely to detect PCa. (p<0.001, p=0.018 and p<0.001, respectively) Conclusion: Several studies have been published with controversial results trying to specify the predictive value of the ratios of white blood cells in diagnosis of PCa. In this study, univariate and multivariate analyses showed that PLR value would be promising for future studies. Prospective studies are needed to find biomarkers for PCa detection.
Archivio Italiano di Urologia e Andrologia, 2019
Objective: To evaluate the diagnostic value of serum inflammation markers derived from complete blood count in diagnosis of prostate cancer (PCa). Methods: We retrospectively analyzed the data of 621 patients who underwent prostate biopsy between March 2013 and April 2018. Age, prostate specific antigen (PSA), free PSA, platelet count, neutrophil count, lymphocyte count, monocyte count, prostate volume (PV) and pathology result of the patients were recorded. Patients were grouped as benign prostatic hyperplasia (BPH), prostatitis and PCa. Patients were also grouped according to PSA values, as PSA < 4 , PSA 4-10 and PSA > 10 ng/dl. Results: The mean lymphocyte-to-monocyte ratio (LMR) value of the patients with PCa was significantly lower in the entire cohort (p = 0.047). In the PSA 4-10 ng/dl range, LMR value wassignificantly lower in patients with PCa than those with BPH or prostatitis (p = 0.012). In this PSA range, free/total PSA ratio and LMR were significant factors to pre...